We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina (ORBITA-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03742050
Recruitment Status : Recruiting
First Posted : November 15, 2018
Last Update Posted : September 6, 2022
Sponsor:
Collaborator:
Basildon and Thurrock Hospitals NHS FoundationTrust
Information provided by (Responsible Party):
Imperial College London

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
ORBITA-2 is a double blinded randomised placebo-controlled trial comparing the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy. Follow-up will be at 12 weeks.

Condition or disease Intervention/treatment Phase
Stable Angina Procedure: Percutaneous coronary intervention Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina
Actual Study Start Date : November 12, 2018
Estimated Primary Completion Date : January 1, 2024
Estimated Study Completion Date : January 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angina Angioplasty

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Percutaneous coronary intervention
Percutaneous coronary intervention with drug-eluting stents and modern techniques
 Procedure: Percutaneous coronary intervention
Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
Other Name: Coronary angioplasty
Placebo Comparator: Placebo percutaneous coronary intervention
Placebo percutaneous coronary intervention
 Procedure: Percutaneous coronary intervention
Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
Other Name: Coronary angioplasty


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in angina symptom score between groups [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Change in treadmill exercise time [ Time Frame: 12 weeks ]
  2. Angina severity as assessed by Canadian Cardiovascular Society class [ Time Frame: 12 weeks ]
  3. Physical limitation, angina stability, quality of life, angina frequency, freedom from angina as assessed with the Seattle Angina Questionnaire [ Time Frame: 12 weeks ]
  4. Quality of life as assessed with the EQ-5D-5L questionnaire [ Time Frame: 12 weeks ]
  5. Change in dobutamine stress echocardiography score [ Time Frame: 12 weeks ]
  6. Need for anti-anginal medication introduction and up-titration [ Time Frame: 12 weeks ]
  7. Admission for acute coronary syndrome or unscheduled coronary angiography [ Time Frame: 12 weeks ]
  8. Freedom from angina on symptom score [ Time Frame: 12 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

ORBITA-2 will enrol patients who meet all 3 of the following criteria:

  1. Angina or angina-equivalent symptoms
  2. Anatomical evidence of significant coronary stenosis in at least one vessel, either: a. Invasive diagnostic coronary angiogram indicating ≥ 70% stenosis b. CT coronary angiography indicating ≥ 90% stenosis

  3. Evidence of ischaemia, arising from at least one of the following options:

    1. Positive dobutamine stress echocardiography
    2. Positive cardiac MRI perfusion scan
    3. Positive nuclear medicine myocardial perfusion scan
    4. Invasive pressure wire assessment suggestive of ischaemia, as judged by the interventional cardiologist, at the time of diagnostic angiogram or research angiogram

Exclusion Criteria:

  1. Age younger than 18
  2. Age older than 85
  3. Recent acute coronary event
  4. Previous coronary artery bypass graft surgery
  5. Significant left main stem coronary disease
  6. Chronic total occlusion in the target vessel
  7. Contraindication to percutaneous coronary intervention or drug-eluting stent implantation
  8. Contraindication to antiplatelet therapy
  9. Severe valvular disease
  10. Severe LV systolic impairment
  11. Severe respiratory disease
  12. Life expectancy less than 2 years, pregnancy, unable to consent
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03742050


Contacts
Layout table for location contacts
Contact: Rasha Al-Lamee, MRCP 020 7594 5735 rasha.al-lamee@nhs.net
Contact: Christopher A Rajkumar, MRCP 020 7594 5735 christopher.rajkumar@nhs.net

Locations
Layout table for location information
United Kingdom
Basildon and Thurrock Hospitals NHS Foundation Trust Recruiting
Basildon, United Kingdom
Contact: Thomas Keeble, MD       thomas.keeble@btuh.nhs.uk   
Royal Bournemouth Hospital Recruiting
Bournemouth, United Kingdom, BH77DW
Contact: Peter O'Kane       peter.o'kane@rbch.nhs.uk   
Wycombe Hospital Recruiting
High Wycombe, United Kingdom, HP11 2TT
Contact: Ricardo Petraco         
Imperial College Healthcare NHS Trust Recruiting
London, United Kingdom, W12 0HS
Contact: Rasha K Al-Lamee, MRCP    07517551868    rasha.al-lamee@nhs.net   
Contact: Christopher A Rajkumar, MRCP    02075945735    christopher.rajkumar@nhs.net   
Principal Investigator: Rasha K Al-Lamee, MRCP         
Royal Free Hospital Recruiting
London, United Kingdom
Contact: Tushar Kotecha         
Queen Alexandra Hospital Recruiting
Portsmouth, United Kingdom
Contact: Peter Haworth         
Royal Berkshire NHS Foundation Trust Recruiting
Reading, United Kingdom
Contact: Neil Ruparelia, MRCP       neil.ruparelia@nhs.net   
Harefield Hospital Recruiting
Uxbridge, United Kingdom, UB9 6JH
Contact: Vas Panoulas       V.Panoulas@rbht.nhs.uk   
Sponsors and Collaborators
Imperial College London
Basildon and Thurrock Hospitals NHS FoundationTrust
Investigators
Layout table for investigator information
Study Chair: Darrel Francis, MRCP Imperial College London
Study Director: Christopher A Rajkumar Imperial College London
Principal Investigator: Rasha Al-Lamee Imperial College London
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT03742050    
Other Study ID Numbers: 18SM4531
First Posted: November 15, 2018    Key Record Dates
Last Update Posted: September 6, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Imperial College London:
Stable Angina
Additional relevant MeSH terms:
Layout table for MeSH terms
Angina Pectoris
Angina, Stable
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
 Vascular Diseases
Chest Pain
Pain
Neurologic Manifestations